SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001209191-20-035745
Filing Date
2020-06-10
Accepted
2020-06-10 21:10:31
Documents
2
Period of Report
2019-11-04

Document Format Files

Seq Description Document Type Size
1 FORM 4/A SUBMISSION doc4a.html 4/A  
1 FORM 4/A SUBMISSION doc4a.xml 4/A 2692
2 POA DOCUMENT poa.txt EX-24.4A_921392 3631
  Complete submission text file 0001209191-20-035745.txt   7729
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address
Ackermann Michael (Reporting) CIK: 0001791249 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-39112 | Film No.: 20956011